Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Year	2023	2022	2021	2020	2019
Net Income	-143.95	-180.36	-117.19	-43.24	-21.7
Depreciation & Amortization	13.65	10.81	6.08	2.18	2.35
Share-Based Compensation	33.67	28.13	15.8	4.3	0.51
Other Operating Activities	15.26	-18.39	10.95	36.68	19.44
Operating Cash Flow	-81.37	-159.81	-84.37	-0.08	0.6
Capital Expenditures	-8.4	-12.24	-5.66	-4.55	-1.65
Change in Investments	76.7	39.44	-102.59	-249.85	10.15
Investing Cash Flow	68.3	27.2	-108.25	-254.4	8.5
Share Issuance / Repurchase	3.22	117.19	153.88	219.11	0.13
Other Financing Activities	-	-	-	119.91	-
Financing Cash Flow	3.22	117.19	153.88	339.02	0.13
Net Cash Flow	-9.85	-15.42	-38.73	84.54	9.23
Free Cash Flow	-89.77	-172.05	-90.03	-4.63	-1.05
Free Cash Flow Margin	-116.60%	-445.42%	-302.61%	-26.00%	-3.37%
Free Cash Flow Per Share	-1.65	-3.54	-2.10	-0.30	-0.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).